 |
54 Diseases |  |
8 Trials |
|
8 Trials |  |
2662 News |  |
| «12...56789101112131415...2324» |
- | ritonavir / Generic mfg., daclatasvir/asunaprevir (BMS-60032/BMS-790052) / BMS
Journal: IL28B Gene Polymorphism Is Correlated with Changes in Low-density Lipoprotein Cholesterol Levels after Clearance of Hepatitis C Virus Using Direct-acting Antiviral Treatment. (Pubmed Central) - Aug 4, 2020
An IL28B polymorphism is associated with ΔLDL-C and hyper-LDL cholesterolemia after achieving SVR. Thus, lipid markers should be carefully monitored in patients who achieve SVR with DAA.
- | Olysio (simeprevir) / J&J, Medivir, ledipasvir/sofosbuvir / Generic mfg.
Preclinical, Journal: Establishment of infectious genotype 4 cell culture-derived hepatitis C virus. (Pubmed Central) - Aug 4, 2020
Both ED43 QS-7M and TS-7M were sensitive to the neutralizing E2 antibodies HCV1 and AR3A and the direct-acting antivirals, simeprevir, ledipasvir and sofosbuvir. In conclusion, we established an infectious ED43 strain containing adaptive mutations, which is important for the analysis of HCV genotype-specific pathogenesis, development of pan-genotypic agents and analysis of drug resistance.
- | ledipasvir/sofosbuvir / Generic mfg.
I took Harvoni for Hep C and it cured it. What is your point (Twitter) - Aug 4, 2020
- || Copegus (ribavirin) / Bausch Health, ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Living donor domino liver transplantation in a hepatitis C virus/human immunodeficiency virus-coinfected hemophilia patient: a case report. (Pubmed Central) - Aug 1, 2020
In conclusion, we established an infectious ED43 strain containing adaptive mutations, which is important for the analysis of HCV genotype-specific pathogenesis, development of pan-genotypic agents and analysis of drug resistance. LDDLT allows successful LT in HCV/HIV-coinfected patients; posttransplant HCV recurrence can be successfully treated with anti-viral therapy.
- || Clinical, Journal: Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa. (Pubmed Central) - Jul 30, 2020
Our outcomes correspond with existing trial and real-world data for similar treatment. DAA therapy and access need rapid upscaling in SA, especially targeting key populations at point of care.
- || Daklinza (daclatasvir) / BMS
Clinical, Journal: Management of HCV in Children in the Era of DAA's. (Pubmed Central) - Jul 29, 2020
Efforts from worldwide health organizations, the pharmaceutical industry, and clinical and research institutions have resulted in very effective interferon-free therapy with direct-acting antiviral agents (DAA's) for HCV-infected children. In this manuscript, we will briefly review the epidemiology of HCV in children, historic treatment, current published data on DAA's in children and conclude with suggestions for management of the child with HCV in the era of DAA's.
- || ledipasvir/sofosbuvir / Generic mfg.
lies once again, one bottle of Harvoni can cost up to 20kEUR (Twitter) - Jul 27, 2020
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal, Real-World Evidence: Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort. (Pubmed Central) - Jul 25, 2020
Lay Summary: Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements of liver function and a reduces the risk of developing a new occurrence of hepatocellular carcinoma.
- || ledipasvir/sofosbuvir / Generic mfg.
Enrollment open: Harvoni Treatment Porphyria Cutanea Tarda (clinicaltrials.gov) - Jul 24, 2020
P2, N=49, Recruiting, Sponsor: Wake Forest University Health Sciences
Eradication is associated with improvements of liver function and a reduces the risk of developing a new occurrence of hepatocellular carcinoma. Active, not recruiting --> Recruiting
- || ledipasvir/sofosbuvir / Generic mfg.
Harvoni was #1 on this list from 2016 https://t.co/5OA7shk0dn (Twitter) - Jul 20, 2020
- ||| sofosbuvir/velpatasvir / Generic mfg., Sovaldi (sofosbuvir) / Gilead, ledipasvir/sofosbuvir / Generic mfg.
That is surprising! It looks like Hepatitis is the most expensive of the GI disorders, which makes sense with the ridiculously high costs of the meds like Sovaldi, Harvoni, and Epclusa (Twitter) - Jul 20, 2020
- Copegus (ribavirin) / Bausch Health
[VIRTUAL] RISK OF OCCURRENCE AND RECURRENCE OF HEPATOCELLULAR CARCINOMA IN 349 PATIENTS WITH LIVER CIRRHOSIS AND HEPATITIS C VIRUS INFECTION GENOTYPE 1 B TREATED WITH SOFOSBUVIR+LEDIPASVIR± RIBAVIRIN (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_5015;
These patients had a low rate of SVR12 (66.7%), and a favorable evolution of paraclinic parameters. The occurrence rate of HCC was 4.7% for a median follow-up period of 20 months.
- Copegus (ribavirin) / Bausch Health
[VIRTUAL] ROLE OF DIRECT ANTIVIRAL TREATMENTS IN THE EVOLUTION OF VIRAL CIRRHOSIS C (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_4979;
This is a retrospective study collecting patients followed for viral cirrhosis C having had antiviral treatment (DAT) (Sofosbuvir / Ledipasvir +/- Ribavirin) between 2016 and 2019. In our series, the SVR rate in patients with viral cirrhosis C was 98% and was associated with a significant decrease in complications except for hepatocellular carcinoma.
- Daklinza (daclatasvir) / BMS
[VIRTUAL] VIROLOGIC RECURRENCE AFTER TREATMENT WITH DIRECT-ACTING ANTIVIRALS IN A COHORT OF PATIENTS WITH CHRONIC HEPATITIS C: PREDICTIVE FACTORS AND RETREATMENT EFFICACY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_4966;
In this real-life cohort, virologic relapse was rare in relation to G3, stage of fibrosis and decompensated cirrhosis. In parallel, there is evidence of effective retreatment options for these patients.
- Copegus (ribavirin) / Bausch Health
[VIRTUAL] REAL WORLD EFFICACY AND SAFETY OF SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS AND HEPATITIS C VIRUS INFECTION: A COHORT STUDY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_4949;
SVR12 rates did not differ significantly between patients with treatment duration of 12 or 24 weeks, and between those treated with Ribavirin or without. The main predictors of SVR were the advanced age and the lower bilirubin levels.
- Copegus (ribavirin) / Bausch Health
[VIRTUAL] RISK OF OCCURRENCE AND RECURRENCE OF HEPATOCELLULAR CARCINOMA IN 349 PATIENTS WITH LIVER CIRRHOSIS AND HEPATITIS C VIRUS INFECTION GENOTYPE 1 B TREATED WITH SOFOSBUVIR+LEDIPASVIR± RIBAVIRIN (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3039;
These patients had a low rate of SVR12 (66.7%), and a favorable evolution of paraclinic parameters. The occurrence rate of HCC was 4.7% for a median follow-up period of 20 months.
- Copegus (ribavirin) / Bausch Health
[VIRTUAL] ROLE OF DIRECT ANTIVIRAL TREATMENTS IN THE EVOLUTION OF VIRAL CIRRHOSIS C (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3003;
This is a retrospective study collecting patients followed for viral cirrhosis C having had antiviral treatment (DAT) (Sofosbuvir / Ledipasvir +/- Ribavirin) between 2016 and 2019. In our series, the SVR rate in patients with viral cirrhosis C was 98% and was associated with a significant decrease in complications except for hepatocellular carcinoma.
- Daklinza (daclatasvir) / BMS
[VIRTUAL] VIROLOGIC RECURRENCE AFTER TREATMENT WITH DIRECT-ACTING ANTIVIRALS IN A COHORT OF PATIENTS WITH CHRONIC HEPATITIS C: PREDICTIVE FACTORS AND RETREATMENT EFFICACY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_2990;
In this real-life cohort, virologic relapse was rare in relation to G3, stage of fibrosis and decompensated cirrhosis. In parallel, there is evidence of effective retreatment options for these patients.
- Copegus (ribavirin) / Bausch Health
[VIRTUAL] REAL WORLD EFFICACY AND SAFETY OF SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS AND HEPATITIS C VIRUS INFECTION: A COHORT STUDY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_2973;
SVR12 rates did not differ significantly between patients with treatment duration of 12 or 24 weeks, and between those treated with Ribavirin or without. The main predictors of SVR were the advanced age and the lower bilirubin levels.
- Copegus (ribavirin) / Bausch Health
[VIRTUAL] RISK OF OCCURRENCE AND RECURRENCE OF HEPATOCELLULAR CARCINOMA IN 349 PATIENTS WITH LIVER CIRRHOSIS AND HEPATITIS C VIRUS INFECTION GENOTYPE 1 B TREATED WITH SOFOSBUVIR+LEDIPASVIR± RIBAVIRIN (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1055;
These patients had a low rate of SVR12 (66.7%), and a favorable evolution of paraclinic parameters. The occurrence rate of HCC was 4.7% for a median follow-up period of 20 months.
- Copegus (ribavirin) / Bausch Health
[VIRTUAL] ROLE OF DIRECT ANTIVIRAL TREATMENTS IN THE EVOLUTION OF VIRAL CIRRHOSIS C (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1019;
This is a retrospective study collecting patients followed for viral cirrhosis C having had antiviral treatment (DAT) (Sofosbuvir / Ledipasvir +/- Ribavirin) between 2016 and 2019. In our series, the SVR rate in patients with viral cirrhosis C was 98% and was associated with a significant decrease in complications except for hepatocellular carcinoma.
- Daklinza (daclatasvir) / BMS
[VIRTUAL] VIROLOGIC RECURRENCE AFTER TREATMENT WITH DIRECT-ACTING ANTIVIRALS IN A COHORT OF PATIENTS WITH CHRONIC HEPATITIS C: PREDICTIVE FACTORS AND RETREATMENT EFFICACY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1006;
In this real-life cohort, virologic relapse was rare in relation to G3, stage of fibrosis and decompensated cirrhosis. In parallel, there is evidence of effective retreatment options for these patients.
- Copegus (ribavirin) / Bausch Health
[VIRTUAL] REAL WORLD EFFICACY AND SAFETY OF SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS AND HEPATITIS C VIRUS INFECTION: A COHORT STUDY (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_989;
SVR12 rates did not differ significantly between patients with treatment duration of 12 or 24 weeks, and between those treated with Ribavirin or without. The main predictors of SVR were the advanced age and the lower bilirubin levels.
- || paritaprevir/ritonavir (ABT-450/r) / AbbVie, Daklinza (daclatasvir) / BMS
Clinical, Journal, Real-World Evidence: Efficacy of direct acting antivirals: UK real world data from a well characterised predominantly cirrhotic HCV cohort. (Pubmed Central) - Jul 9, 2020
This real world UK data, comprising of a predominantly cirrhotic HCV genotype 1/3 cohort, confirms DAA efficacy with an overall 91% SVR12, with 51% recompensating post treatment. Genotype 3 infection was a predictor of treatment failure.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 weeks. (Pubmed Central) - Jul 8, 2020
SVR12 rates for SL8 among HCV-monoinfected and HIV/HCV-coinfected patients were: 96.3% vs. 92.2% (p=0.243), respectively. The corresponding relapse rates were 0.9% vs. 4.9% (p=0.112).
- | Daklinza (daclatasvir) / BMS
New P4 trial: Effect of Hepatitis C Clearance on Insulin Resistance (clinicaltrials.gov) - Jul 6, 2020
P4, N=160, Completed, Sponsor: Alexandria University
- | ledipasvir/sofosbuvir / Generic mfg.
Journal: Telemedicine, prison and illness associated with HIV (Pubmed Central) - Jul 4, 2020
This type of consultation has a growing demand, is efficient (avoids transfers and is decisive) and has high acceptance. The most frequent reason for consultation was the treatment of HCV and more than a third of patients required ART change.
- || ledipasvir/sofosbuvir / Generic mfg.
Clinical, Journal: Twelve Weeks of Ledipasvir/Sofosbuvir All-oral Regimen for Patients with Chronic Hepatitis C Genotype 2 Infection: Integrated Analysis of Three Clinical Trials. (Pubmed Central) - Jul 3, 2020
LDV/SOF for 12 weeks provides a highly effective and safe treatment for patients with genotype 2 HCV, including those with advanced fibrosis. As a ribavirin-free and protease inhibitor-free regimen with minimal on-treatment monitoring requirements, LDV/SOF can potentially play a crucial role in achieving the World Health Organization's goal of HCV elimination.
- [VIRTUAL] EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4947;
DAAs treatment was effective, safe and feasible in this cohort of mainly allogeneic HCT recipients with mild-to-moderate liver damage. Side effects were usually haematological and more frequent in case of ribavirin-containing regimens.
- [VIRTUAL] EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4946;
DAAs treatment was effective, safe and feasible in this cohort of mainly allogeneic HCT recipients with mild-to-moderate liver damage. Side effects were usually haematological and more frequent in case of ribavirin-containing regimens.
- [VIRTUAL] EFFICACY, SAFETY AND FEASIBILITY OF TREATMENT OF CHRONIC HCV INFECTION WITH DIRECTLY ACTING AGENTS (DAAS) IN HCT RECIPIENTS - EBMT INFECTIOUS DISEASES WORKING PARTY STUDY (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4945;
DAAs treatment was effective, safe and feasible in this cohort of mainly allogeneic HCT recipients with mild-to-moderate liver damage. Side effects were usually haematological and more frequent in case of ribavirin-containing regimens.
- | velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS, elbasvir (MK-8742) / Merck (MSD)
Preclinical, Journal: Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice. (Pubmed Central) - Jul 2, 2020
Side effects were usually haematological and more frequent in case of ribavirin-containing regimens. Therapies combining at least two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents may be effective for HCV-infected patients with NS5A-P32del.
- | Sovaldi (sofosbuvir) / Gilead, ledipasvir/sofosbuvir / Generic mfg.
Retrospective data, Journal: Efficacy and safety of sofosbuvir-containing regimens in patients with chronic hepatitis C virus infection after liver transplantation: a meta-analysis. (Pubmed Central) - Jun 23, 2020
The results of this study showed that the treatment response of SOF-containing regimens in patients with HCV infection after LT was satisfactory. However, more attention needs to be paid to the high rate of AEs associated with such regimens.
- Copegus (ribavirin) / Bausch Health, ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] High SVR with ledipasvir/sofosbuvir +/- ribavirin among PWID and PWH in Ukraine (Poster Channel - Track B) - Jun 22, 2020 - Abstract #AIDS2020AIDS_2352;
- metformin / Generic mfg.
[VIRTUAL] Treatment of Hepatitis C Has Time-Dependent Relationship with Type 2 Diabetes Progress () - Jun 20, 2020 - Abstract #ENDOI2020ENDO-I_999;
Prior to HCV treatment patient DM control was treated with oral medications (metformin and glipizide) with fast glucose level fluctuating 143±44 mg/dl; 2 hours postprandial level 205±57mg/dl; HbA1c 7.0%...Oral DM medications were doubled dosages and maximum dosage of pioglitazone was added on...Discussion Based on our observation there are four phases of DM development related to the HCV treatment: phase I silence stage (during 3 month HCV treatment) DM is stable; phase II deterioration stage (First 3 month after HCV treatment) DM is progressively getting worse; phase III recovery stage (4 to 6 month after HCV treatment) DM is gradually improving; phase IV stabilization stage (6 month after HCV treatment) DM is stabilized and improved. Conclusion Anti-viral treatment of HCV has possible intrinsic time-dependent relationship with DM development.
- | elbasvir (MK-8742) / Merck (MSD)
Journal: Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments. (Pubmed Central) - Jun 15, 2020
List price reductions for hepatitis C treatments may have increased drug manufacturer net revenues, owing in part to lower discounts provided under the 340B program and the high share of sales subject to those discounts. Policymakers should consider the role of 340B discounts when evaluating policies to reduce drug spending.
- || Clinical, Journal: Changing demographics among populations prescribed HCV treatment, 2013-2017. (Pubmed Central) - Jun 12, 2020
Policymakers should consider the role of 340B discounts when evaluating policies to reduce drug spending. In the United States, since the introduction of interferon-free HCV regimens, the patient population prescribed treatment has changed, becoming predominantly treatment-naïve, without cirrhosis, and treated in nonacademic centers.
- | pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
Journal: First Reported Treatment Failure in a Recipient of a Hepatitis C Viremic Heart Transplant. (Pubmed Central) - May 30, 2020
In the new era of HCV transplantation, selection of DAA and duration of treatment are critical. Awareness of the resistance development data is needed when selecting HCV treatment regimens.
- Copegus (ribavirin) / Bausch Health, ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] Impact of direct antiviral agents (DAAs) on the HBV virologic profile in HCV+ but HBsAg- and HBcAb+ patients (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1795;
However, the elevation of HBV VL remains low, with no clinico-biological consequences. Virological HBV monitoring is advised at the end of treatment.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta, sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] Pangenotypic therapies glecaprevir-pibrentasvir (G-P) and sofosbuvir-velpatasvir-voxilaprevir (S-V-V) after failure with interferon (IFN)-free direct-acting antiviral (DAA) treatment for hepatitis C (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1790;
G-P and S-V-V treatment groups were not significantly different for age, gender, insurance, ribavirin, anxiety, depression, diabetes, HCC, HIV, or HBV and had characteristics of GT1 (82% G-P v. 78% S-V-V, p=0 .589) and baseline FIB4 >3.25 (37% G-P v. 38% S-V-V, p=0.651)...Prior therapy was mostly ledipasvir-sofosbuvir (L-S) for both G-P (64%) and S-V-V (58%)... In patients with prior DAA failure/relapse, significantly higher ITT and PP SVR rates were observed with S-V-V compared to G-P both before and after adjustment for clinical differences.
- ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] Economic evaluation of the hepatitis C virus screening and treatment program in Georgia (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1714;
The first phase of the HCV elimination program was highly cost-effective in Georgia. This provides valuable data on efficiency of national programmes for scaling up HCV treatment for achieving HCV elimination.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie, velpatasvir (GS-5816) / Gilead
[VIRTUAL] Hepatitis C positive organ transplantation to negative recipients at a multi-organ Canadian transplant centre: ready for prime time (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-837;
Using HCV positive organs is safe and may further expand the donor pool. In patients that have HCV transmission post-transplant DAAs are efficacious with no significant adverse events, intolerance, or graft failure.
- ledipasvir/sofosbuvir / Generic mfg., methadone / Generic mfg.
[VIRTUAL] Effectiveness of new generation DAAs for HCV infection in a large cohort of Italian people who use drugs (PWID): the cleo-grecas real-world experience (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-836;
Low rate of drop-out was mainly due to the continuum of care programme inside SerDs. Our results launch this model as best practice to manage this kind of patients worldwide.
- sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] Management of hepatitis C in primary healthcare in the country of Georgia (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-832;
Our study reported the feasibility and effectiveness of integrating a simplified HCV diagnostic and treatment model in PHCs. Countrywide expansion of this model is warranted to bridge the gaps in the HCV care continuum and ensure high rates of treatment uptake towards achieving elimination targets.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] In-depth molecular characterization of inherently resistant African HCV genotype 1, subtype 1l, in patients failing DAA-based therapy (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-827;
The large number of NS5A RASs present at baseline explains lower SVR rates with NS5A inhibitor- based therapies in these patients. Our results emphasize the need for identification of this subtype and other “unusual” subtypes (e.g.
- Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, sofosbuvir/velpatasvir / Generic mfg.
[VIRTUAL] Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-820;
In this real-world cohort of patients with virological failure after prior DAA therapy, retreatment with SOF/VEL/VOX resulted in SVR rates of more than 90% across all genotypes; however, SVR was lower for those with underlying cirrhosis. Comparisons were limited by small sample sizes.
- pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
[VIRTUAL] Real-life experience of direct acting antiviral treatment for chronic hepatitis C infection in adolescent patients in a low prevalence setting (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-815;
Challenges with DAT in our patient cohort included; 1) adherence with treatment protocol 2) complex social backgrounds and 3) coordination of DAT monitoring with educational examinations. To ensure optimal success of DAT in a non clinical trial setting we suggest careful patient selection, advanced patient preparation, ongoing patient follow up and parental/guardian support from a multidisciplinary team.
- ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction services in Kenya (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-814;
These results need to be interpreted with caution given those who were most interested were retained for HCV treatment in this sub-study. Additional studies will be required to assess optimal models of care for HCV treatment among PWID in LMICs given DOT may be infeasible when resources are not sufficient.
- Sovaldi (sofosbuvir) / Gilead
[VIRTUAL] Use of sofosbuvir based direct acting antiviral regimens is associated with reduced mortality in liver transplant candidates with hepatitis C (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-798;
In a contemporary national cohort, only a minority of waitlisted HCV positive liver transplant candidates were treated with SOF containing DAAs. However, SOF use was associated with reduced all-cause mortality and increased removal from the waitlist due to improved condition which suggests that HCV treatment should be considered in all HCV infected liver transplant candidates.
- ledipasvir/sofosbuvir / Generic mfg.
[VIRTUAL] Characteristics of adults with difficult-to-treat hepatitis C virus genotype subtype 4r infection in Rwanda: a secondary analysis of a clinical trial in Sub-Saharan Africa (shared study) (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-791;
In the absence of advanced diagnostics to assess GT subtype, patients with these characteristics may warrant closer monitoring for treatment failure or alternative DAA regimens. More treatment experience with diverse DAA regimens is urgently needed for GT subtypes particular to this region.